Who We Are

Kineta is a privately held emerging biotech company that was founded in 2008. Our mission is to develop novel immuno-therapies that transform patients’ lives. Kineta has established a focused pipeline of life improving therapies that address critical unmet patient needs. We have leveraged our expertise in immunology to advance novel drug development programs in oncology, neuroscience and virology.

We actively collaborate with a broad array of private, government and industry partners to advance our innovative research. Kineta fills a void in the biopharmaceutical industry by efficiently advancing first in class immunotherapies from discovery to clinical proof of concept.